ARA-290 potentially reduces inflammation, alleviates neuropathic pain, and promotes tissue repair without increasing red blood cell production. It offers potential benefits for conditions like small fiber neuropathy and type 2 diabetes. ARA-290 is a synthetic peptide derived from erythropoietin (EPO). It selectively targets the innate repair receptor (IRR) to reduce inflammation, modulate neuropathic pain, and promote tissue repair. Unlike EPO, ARA-290 does not promote red blood cell production, making it a safer alternative for addressing inflammatory and neurodegenerative conditions. It selectively activates repair pathways, offering potential benefits for conditions like small fiber neuropathy and type 2 diabetes.
ARA-290
Also known as: Cibinetide; PH-BSP
Overview
Benefits
- Neuropathic pain relief
- Regulates blood sugar
- Protects neurons from oxidative stress
- May contribute to better lipid profiles
- Inflammation reduction
Consider This Peptide If You Want To
- Experience neuropathic pain or small fiber neuropathy and want relief without erythropoietin-related risks
- Reduce inflammation and promote tissue repair, e.g., in type 2 diabetes or chronic inflammatory disorders
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount: 4 mg
• Frequency: daily
• Duration: 4 weeks
• Rest Period: 4 weeks
• Time of Day: morning
• Ingestion: subcutaneous
- Subcutaneous
Research Findings on Dosage:
• Commonly Reported Dosage: 4 mg daily
• Note: ARA-290 is soluble in alkaline solutions and may appear cloudy when reconstituted with bacteriostatic water. This is normal and not an indication of a product quality issue.
• Duration: 30 days on, 30 days off
• Note: ARA-290 is soluble in alkaline solutions and may appear cloudy when reconstituted with bacteriostatic water. This is normal and not an indication of a product quality issue.
• Duration: 30 days on, 30 days off
Mechanism of Action
How this peptide works in the body
• ARA-290 binds to the innate repair receptor (IRR), a heterodimer of erythropoietin receptor (EPOR) and CD131, triggering the JAK2/STAT5 signaling pathway to regulate inflammation and cellular repair. This activation inhibits NF-κB, reducing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, leading to anti-inflammatory and cytoprotective effects.
Neuroprotection and Tissue Repair:
Non-Erythropoietic Activity:
• Unlike erythropoietin (EPO), ARA-290 does not bind to homodimeric EPOR receptors, thereby avoiding erythropoiesis (red blood cell production). This allows it to provide tissue-protective and anti-inflammatory effects without increasing hematocrit or thrombosis risk.
Non-Erythropoietic Activity:
• Unlike erythropoietin (EPO), ARA-290 does not bind to homodimeric EPOR receptors, thereby avoiding erythropoiesis (red blood cell production). This allows it to provide tissue-protective and anti-inflammatory effects without increasing hematocrit or thrombosis risk.
Consider Stacking With
Side Effects & Cautions
Common Side Effects
- Mild injection site redness or irritation
Research & References
Research Highlights
1. Small Fiber Neuropathy:
• Study Population: Patients with sarcoidosis-associated neuropathy.
• Findings: ARA-290 improved symptoms and increased corneal nerve fiber density.
2. Metabolic Improvements:
• In patients with type 2 diabetes, ARA-290 reduced HbA1c and improved neuropathic symptoms.
3. Safety Profile:
• Well-tolerated in clinical trials with minimal side effects.
• Peptide Sciences Summary of ARA-290
• Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy (PubMed)
• ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density (PubMed)
• ARA 290 Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes (PubMed)
• Small Fiber Neuropathy and ARA-290 Results (Video)
• Small Fiber Neuropathy and ARA-290 Results (Video)